Is Zymeworks Common Stock a Good Investment?
Zymeworks Common Investment Advice | ZYME |
- Examine Zymeworks Common's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Zymeworks Common's leadership team and their track record. Good management can help Zymeworks Common navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Zymeworks Common's business and its evolving consumer preferences.
- Compare Zymeworks Common's performance and market position to its competitors. Analyze how Zymeworks Common is positioned in terms of product offerings, innovation, and market share.
- Check if Zymeworks Common pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Zymeworks Common's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Zymeworks Common Stock stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Zymeworks Common Stock is a good investment.
Sell | Buy |
Strong Hold
Market Performance | OK | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Zymeworks Common Stock
Researching Zymeworks Common's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company outstanding shares are owned by institutional investors. The book value of Zymeworks Common was at this time reported as 5.27. The company recorded a loss per share of 1.49. Zymeworks Common Stock had not issued any dividends in recent years.
To determine if Zymeworks Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zymeworks Common's research are outlined below:
| The company reported the previous year's revenue of 76.01 M. Net Loss for the year was (118.67 M) with profit before overhead, payroll, taxes, and interest of 203.78 M. | |
| Zymeworks Common Stock currently holds about 241.83 M in cash with (118.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.18. | |
| Over 99.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Y-mAbs Therapeutics, Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat |
Zymeworks Common Quarterly Accounts Payable |
|
Zymeworks Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zymeworks Common Stock. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zymeworks Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Zymeworks Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Zymeworks Common's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-01 | 2024-06-30 | -0.32 | -0.27 | 0.05 | 15 | ||
2023-11-07 | 2023-09-30 | -0.47 | -0.41 | 0.06 | 12 | ||
2018-11-06 | 2018-09-30 | -0.67 | -0.59 | 0.08 | 11 | ||
2020-08-05 | 2020-06-30 | -0.86 | -0.77 | 0.09 | 10 | ||
2017-11-08 | 2017-09-30 | -0.54 | -0.64 | -0.1 | 18 | ||
2019-05-02 | 2019-03-31 | -0.54 | -0.43 | 0.11 | 20 | ||
2024-05-02 | 2024-03-31 | -0.29 | -0.42 | -0.13 | 44 | ||
2018-05-01 | 2018-03-31 | -0.68 | -0.83 | -0.15 | 22 |
Know Zymeworks Common's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Zymeworks Common is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zymeworks Common Stock backward and forwards among themselves. Zymeworks Common's institutional investor refers to the entity that pools money to purchase Zymeworks Common's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Farallon Capital Management, L.l.c. | 2024-09-30 | 1.4 M | State Street Corp | 2024-09-30 | 1.2 M | Nextech Invest Ag | 2024-09-30 | 1.1 M | Tang Capital Management Llc | 2024-09-30 | 1.1 M | Samsara Biocapital, Llc | 2024-09-30 | 1000 K | Prosight Management, Lp | 2024-09-30 | 917.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 849.5 K | Bridgeway Capital Management, Llc | 2024-09-30 | 742.6 K | Geode Capital Management, Llc | 2024-09-30 | 713.9 K | Ecor1 Capital, Llc | 2024-09-30 | 13.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 5.1 M |
Zymeworks Common's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 993.21 M.Market Cap |
|
Zymeworks Common's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.26) | (0.28) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.26) | (0.27) |
Determining Zymeworks Common's profitability involves analyzing its financial statements and using various financial metrics to determine if Zymeworks Common is a good buy. For example, gross profit margin measures Zymeworks Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Zymeworks Common's profitability and make more informed investment decisions.
Please note, the presentation of Zymeworks Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zymeworks Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zymeworks Common's management manipulating its earnings.
Evaluate Zymeworks Common's management efficiency
Zymeworks Common Stock has return on total asset (ROA) of (0.1469) % which means that it has lost $0.1469 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2873) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.23. In addition to that, Return On Capital Employed is expected to decline to -0.28. At present, Zymeworks Common's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.12, whereas Non Currrent Assets Other are forecasted to decline to about 5.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.75 | 3.90 | |
| Tangible Book Value Per Share | 6.21 | 3.29 | |
| Enterprise Value Over EBITDA | (4.50) | (4.72) | |
| Price Book Value Ratio | 1.54 | 1.46 | |
| Enterprise Value Multiple | (4.50) | (4.72) | |
| Price Fair Value | 1.54 | 1.46 | |
| Enterprise Value | 584.7 M | 673.9 M |
Zymeworks Common Stock has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 1.157 |
Basic technical analysis of Zymeworks Stock
As of the 2nd of December, Zymeworks Common maintains the Market Risk Adjusted Performance of 0.4007, downside deviation of 2.41, and Mean Deviation of 2.03. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zymeworks Common Stock, as well as the relationship between them. Please check out Zymeworks Common Stock variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Zymeworks Common Stock is priced fairly, providing market reflects its latest price of 14.09 per share. Given that Zymeworks Common Stock has jensen alpha of 0.2384, we strongly advise you to confirm Zymeworks Common Stock's prevalent market performance to make sure the company can sustain itself at a future point.Zymeworks Common's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zymeworks Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zymeworks Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zymeworks Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zymeworks Common's Outstanding Corporate Bonds
Zymeworks Common issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zymeworks Common Stock uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zymeworks bonds can be classified according to their maturity, which is the date when Zymeworks Common Stock has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Zymeworks Common's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Zymeworks Common's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1042 | |||
| Market Risk Adjusted Performance | 0.4007 | |||
| Mean Deviation | 2.03 | |||
| Semi Deviation | 2.05 | |||
| Downside Deviation | 2.41 | |||
| Coefficient Of Variation | 789.22 | |||
| Standard Deviation | 2.87 | |||
| Variance | 8.26 | |||
| Information Ratio | 0.0788 | |||
| Jensen Alpha | 0.2384 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.0938 | |||
| Treynor Ratio | 0.3907 | |||
| Maximum Drawdown | 17.12 | |||
| Value At Risk | (3.12) | |||
| Potential Upside | 4.74 | |||
| Downside Variance | 5.83 | |||
| Semi Variance | 4.2 | |||
| Expected Short fall | (2.24) | |||
| Skewness | 0.8815 | |||
| Kurtosis | 2.67 |
| Risk Adjusted Performance | 0.1042 | |||
| Market Risk Adjusted Performance | 0.4007 | |||
| Mean Deviation | 2.03 | |||
| Semi Deviation | 2.05 | |||
| Downside Deviation | 2.41 | |||
| Coefficient Of Variation | 789.22 | |||
| Standard Deviation | 2.87 | |||
| Variance | 8.26 | |||
| Information Ratio | 0.0788 | |||
| Jensen Alpha | 0.2384 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.0938 | |||
| Treynor Ratio | 0.3907 | |||
| Maximum Drawdown | 17.12 | |||
| Value At Risk | (3.12) | |||
| Potential Upside | 4.74 | |||
| Downside Variance | 5.83 | |||
| Semi Variance | 4.2 | |||
| Expected Short fall | (2.24) | |||
| Skewness | 0.8815 | |||
| Kurtosis | 2.67 |
Consider Zymeworks Common's intraday indicators
Zymeworks Common intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zymeworks Common stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Zymeworks Common Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 29th of October 2024 Other Reports | ViewVerify |
Zymeworks Stock media impact
Far too much social signal, news, headlines, and media speculation about Zymeworks Common that are available to investors today. That information is available publicly through Zymeworks media outlets and privately through word of mouth or via Zymeworks internal channels. However, regardless of the origin, that massive amount of Zymeworks data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zymeworks Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zymeworks Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zymeworks Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zymeworks Common alpha.
Zymeworks Common Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Zymeworks Common Corporate Directors
| Thomas Kreudenstein | Director Engineering | Profile | |
| Nina Weisser | Director Therapeutics | Profile | |
| Lota Zoth | Lead Independent Director | Profile | |
| Shrinal Inamdar | Director Relations | Profile |
Already Invested in Zymeworks Common Stock?
The danger of trading Zymeworks Common Stock is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zymeworks Common is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zymeworks Common. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zymeworks Common Stock is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.831 | Quarterly Revenue Growth (0.03) | Return On Assets (0.15) | Return On Equity (0.29) |
The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Zymeworks Common's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.